Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Dyno Therapeutics
AddedFeb 15, 2024
UpdatedJun 18, 2026
Dyno Therapeutics

Dyno Therapeutics

Dyno Therapeutics: AI-powered biotech startup engineering effective gene therapies.

HQ
Cambridge, MA, US
Founded
2018
Overview
Compare
Fundraising
Employees
Website

Dyno Therapeutics is a biotech company focused on revolutionizing gene therapy through AI-powered engineering of Adeno-associated Virus (AAV) capsids. The company aims to enhance the delivery and efficacy of gene therapies by leveraging next-generation DNA technologies and machine learning. Based in Cambridge, Dyno Therapeutics develops innovative solutions for more effective treatment of genetic disorders.

The company has formed strategic partnerships with major pharmaceutical firms, including Astellas, Roche, Sarepta, and Novartis, to advance gene therapy applications in various areas such as skeletal and cardiac muscle, CNS, liver, and ocular diseases. Dyno Therapeutics has secured Series A financing and is working on reducing the cost of gene therapy development while improving performance through advanced AI technologies and biological sequence design.

Dyno Therapeutics - Similar Companies

Apertura Gene Therapy logo

Apertura Gene Therapy

aperturagtx.com

Aavogen logo

Aavogen

aavogen.com

Affinia Therapeutics logo

Affinia Therapeutics

affiniatx.com

Capsida Biotherapeutics logo

Capsida Biotherapeutics

capsida.com

Kate Therapeutics logo

Kate Therapeutics

Exegenesis Bio logo

Exegenesis Bio

exegenesisbio.com

1910 logo

1910

1910genetics.com

Synvivia logo

Synvivia

synvivia.com

Code Biotherapeutics logo

Code Biotherapeutics

codebiotx.com

Bedrock Therapeutics logo

Bedrock Therapeutics

Gensaic logo

Gensaic

gensaic.com

Asimov logo

Asimov

asimov.com

Lacerta Therapeutics logo

Lacerta Therapeutics

20n logo

20n

Atsena Therapeutics logo

Atsena Therapeutics

atsenatx.com

Dyno Therapeutics - Quick Facts

Who are Dyno Therapeutics' competitors?

Companies similar to Dyno Therapeutics include Apertura Gene Therapy, Aavogen, Affinia Therapeutics and Capsida Biotherapeutics.

When was Dyno Therapeutics founded?

Dyno Therapeutics was founded in 2018.

Where is Dyno Therapeutics' headquarters located?

Dyno Therapeutics' headquarters is located in Cambridge, MA, US.

When was Dyno Therapeutics' last funding round?

Dyno Therapeutics' most recent funding round was for $100M (USD) in May 2021.

How much has Dyno Therapeutics raised to-date?

As of May 6, 2021, Dyno Therapeutics has raised a total of $109M (USD).

How many employees does Dyno Therapeutics have?

Dyno Therapeutics has 133 employees as of Feb 4, 2024.

Dyno Therapeutics - Classification

Ownership
  • Venture Capital
Technology
  • AI
  • Machine Learning
Geographic Exposure
  • Global
Revenue
  • Licensing
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Gene Therapy
Tags
  • AI Operations
  • Biotech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software